MAM
FATE icon

Meeder Asset Management’s Fate Therapeutics FATE Stock Holding History

Meeder Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,949
Closed -$175K – 1559
2021
Q3 		$175K Sell
2,949
-279
-9% -$21.9K 0.01% 762
2021
Q2 		$280K Buy
3,228
+330
+11% +$26.6K 0.01% 654
2021
Q1 		$239K Buy
+2,898
New +$278K 0.01% 684
2020
Q4 		– Sell
-2,133
Closed -$84K – 1982
2020
Q3 		$84K Sell
2,133
-3,101
-59% -$108K 0.01% 829
2020
Q2 		$180K Buy
5,234
+662
+14% +$19.7K 0.01% 623
2020
Q1 		$101K Buy
4,572
+2,543
+125% +$64.3K 0.01% 713
2019
Q4 		$39K Buy
2,029
+640
+46% +$10.2K ﹤0.01% 1102
2019
Q3 		$21K Sell
1,389
-8,719
-86% -$167K ﹤0.01% 1290
2019
Q2 		$205K Buy
10,108
+7,282
+258% +$131K 0.01% 572
2019
Q1 		$50K Buy
2,826
+2,015
+248% +$31.8K ﹤0.01% 880
2018
Q4 		$10K Buy
811
+178
+28% +$2.48K ﹤0.01% 1243
2018
Q3 		$10K Sell
633
-1,953
-76% -$23.1K ﹤0.01% 1159
2018
Q2 		$29.3K Buy
2,586
+1,452
+128% +$16K ﹤0.01% 884
2018
Q1 		$12K Buy
1,134
+917
+423% +$8.79K ﹤0.01% 1018
2017
Q4 		$1K Buy
+217
New +$968 ﹤0.01% 1564

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Meeder Asset Management's FATE Position: Q4 2021 in Review

Meeder Asset Management sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 2,949 shares — an estimated $175K sold.

Meeder Asset Management first reported a position in FATE in Q4 2017 and held it in 15 quarters. The position peaked at $280K in Q2 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Meeder Asset Management reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 2,949 Fate Therapeutics shares in Q4 2021, an estimated $175K.
  • Meeder Asset Management first reported a position in Fate Therapeutics in Q4 2017 and held it in 15 quarters.
  • Meeder Asset Management's Fate Therapeutics position peaked at $280K in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.